Chutes & Ladders—BridgeBio oncology execs take the reins of new spinout

Chutes and LaddersWelcome to this week’s Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week. 

BridgeBio’s oncology team takes the reins of new spinout

BridgeBio Oncology Therapeutics

With BridgeBio’s attention squarely on seeing acoramidis through regulatory approval, the company is slicing off its oncology unit as a standalone company. 

Leaders of the existing unit are joining the move, with oncology R&D chief Eli Wallace, Ph.D., named as CEO. Pedro Beltran, Ph.D., head of biology, will be the spinout’s CSO. BridgeBio Oncology Therapeutics—a name that clearly prioritizes clarity over wit—will be chaired by University of California, San Francisco scientist Frank McCormick, Ph.D.

The new company, which will focus on RAS-driven tumors, has been equipped with $200 million…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks